MONTREAL & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Repare Therapeutics today announced that it has been named by FierceBiotech as one of 2017’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.
“We are honored to be named a 2017 Fierce 15 company,” said Lloyd Segal, president and chief executive officer of Repare Therapeutics. “For over two years our team has been working on new ways to bring precision medicine to cancer. We’ve built a world-class organization and have succeeded at forging a leading position in the field of applied DNA Damage Repair research. The Fierce 15 award is a testament to our progress and success to-date, while the biggest challenges – notably delivering impactful new drugs to cancer patients – are ahead of us.”
The Fierce 15 celebrates the spirit of being "fierce" – championing innovation and creativity, even in the face of intense competition. This is FierceBiotech's fifteenth annual Fierce 15 selection. Each annual Fierce 15 selection highlights privately held companies that are working to develop products, services, or platforms that can advance the biotech industry and transform patient treatment. Companies are selected based on a variety of factors such as the strength of their technology, partnerships, venture backers and a competitive market position.
About FierceBiotech
An internationally recognized daily report reaching a network of more than 275,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with an authoritative analysis of the day's top stories. Every business day, FierceBiotech and its family of publications covers the waterfront in drug development, from pre-clinical science to seed funding and venture capital, through IPOs and licensing, clinical testing, regulatory changes, M&A and beyond.
FierceBiotech is a publication of Questex LLC. Signup is free on this registration page.
About Repare Therapeutics
Repare is developing new, precision oncology drugs for patients that target specific vulnerabilities of tumor cells. Its approach integrates insights from several fields of cell biology including DNA repair and synthetic lethality. Repare’s platform combines a proprietary, high-throughput, CRISPR-enabled gene editing target discovery method with high-resolution protein crystallography, computational biology and clinical informatics. The company is backed by leading global healthcare investors including founding investor Versant Ventures and MPM Capital. For additional information, please visit www.reparerx.com.
